Concurrent acalabrutinib, bendamustine, and rituximab in the first-line setting improved outcomes for patients with mantle cell lymphoma (MCL) relative to sequential treatment without acalabrutinib.

In chronic myeloid leukemia, combining asciminib with a tyrosine kinase inhibitor shows increasing efficacy and tolerability over 3 years.

Removing etoposide did not negatively affect OS, DFS, MRD, or relapse rate at 3 years for pediatric patients with LR1, LR2 or high-risk AML.

Many families with children being treated for acute lymphoblastic leukemia face household material hardship and/or income loss.

Epcoritamb plus lenalidomide and rituximab improves PFS and complete response in patients with relapsed/refractory follicular lymphoma in second line compared with lenalidomide and rituximab alone.

A treatment strategy of targeted therapy first allowed more than half of patients with newly diagnosed DLBCL to achieve a CR without chemotherapy.

In patients with follicular lymphoma being treated in the third-line setting or later, liso-cel therapy is associated with durable responses.

Targeted immunotherapy significantly improved responses and prolonged survival in newly-diagnosed Ph+ ALL compared with chemotherapy.

KRd significantly prolonged progression-free survival and improved the MRD negativity rate compared to VRd in newly diagnosed multiple myeloma.

The Isa-VRd quadruplet regimen induced sustained MRD negativity and a strong rate complete response or better in patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

Treatment with rituximab plus epcoritamab has achieved rapid and deep responses in follicular lymphoma patients with a high tumor burden.

Investigators analyzed IBD subtypes and their associated risks of radical prostatectomy complications among a cohort of patients with prostate cancer to fill a knowledge gap.